Peter Vandenberghe
- Hematology top 0.2%
- Acute Myeloid Leukemia Research 39
- Chronic Myeloid Leukemia Treatments 27
- Genetics top 0.5%
- Chronic Lymphocytic Leukemia Research 34
- Pathology and Forensic Medicine top 0.2%
- Lymphoma Diagnosis and Treatment 57
- Immunology top 0.5%
- Immune Cell Function and Interaction 37
- T-cell and B-cell Immunology 27
- Oncology top 1%
-
- Eosinophilic Disorders and Syndromes 21
-
- Acute Lymphoblastic Leukemia research 19
- Co-authors
- Jan CeuppensGregor VerhoefJan CoolsIwona WłodarskaSigrid StroobantsKaroline SpaepenJosé ThomasMark de Boer
- Partner nations
- BelgiumUnited StatesNetherlands
In The Last Decade
Peter Vandenberghe
219 papers receiving 10.5k citations
Hit Papers
Peers
Comparison fields: 5 of 135
- Hematology 2.3k
- Genetics 1.6k
- Pathology and Forensic Medicine 2.4k
- Immunology 2.7k
- Oncology 2.2k
Countries citing papers authored by Peter Vandenberghe
This map shows the geographic impact of Peter Vandenberghe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Vandenberghe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Vandenberghe more than expected).
Fields of papers citing papers by Peter Vandenberghe
This network shows the impact of papers produced by Peter Vandenberghe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Vandenberghe. The network helps show where Peter Vandenberghe may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Peter Vandenberghe, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 2 | |
| 2 | 2024 | 35 | |
| 3 | Selinexor, Bortezomib and Dexamethasone: An Effective Salvage Regimen for Heavily Pretreated Myeloma Patients | 2022 | 5 |
| 4 | 2021 | 18 | |
| 5 | 2021 | 8 | |
| 6 | 2018 | 63 | |
| 7 | 2018 | 14 | |
| 8 | 2010 | 68 | |
| 9 | A novel t(4;9)(q21;p24) fuses SEC31A to JAK2 in nodular-sclerosis Hodgkin lymphoma | 2008 | 2 |
| 10 | 2008 | 58 | |
| 11 | Management of molecular resistance in a patient with fip1l1-pdgfra positive eosinophilic leukemia | 2008 | 1 |
| 12 | Flow cytometric analysis of oncogenic signal transduction pathways in primary leukaemic cells | 2008 | 1 |
| 13 | 5-aza-2 '-deoxycytidine can induce differentiation of clonal abnormal progenitor cells from patients with myelodysplastic syndromes without induction of apoptosis | 2008 | 4 |
| 14 | Array-CGH mapping of an overrepresented 7Q region in gamma/delta hepatosplenic T-cell lymphoma | 2008 | 1 |
| 15 | New 9p24 abnormalities in hematological malignancies | 2007 | 1 |
| 16 | Hodgkin's lymphoma: Response assessment by revised international workshop criteria | 2007 | 1 |
| 17 | Intensive non-myeloablative chemotherapy can induce GvHD and complete remission in patients with AML/MDS relapsing after allo-BMT | 1998 | 1 |
| 18 | Granulocyte-macrophage colony-stimulating factor (GM-CSF) fails to improve outcome in invasive fungal infections in neutropenic cancer patients | 1996 | 1 |
| 19 | Treatment of patients with myelodysplastic syndromes with allogeneic bone marrow transplantation from genotypically HLA-identical sibling and alternative donors. | 1996 | 31 |
| 20 | Ligation of the CD5 or CD28 molecules on resting human T cells induces expression of the early activation antigen CD69 by a calcium- and tyrosine kinase-dependent mechanism. | 1993 | 34 |
About Peter Vandenberghe
Peter Vandenberghe is a scholar working on Hematology, Genetics, Pathology and Forensic Medicine, Immunology and Oncology, having authored 229 papers that have together received 10.7k indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (57 papers), Acute Myeloid Leukemia Research (39 papers), Immune Cell Function and Interaction (37 papers), Chronic Lymphocytic Leukemia Research (34 papers), T-cell and B-cell Immunology (27 papers), Chronic Myeloid Leukemia Treatments (27 papers), Eosinophilic Disorders and Syndromes (21 papers) and Acute Lymphoblastic Leukemia research (19 papers). The work is most often cited by research in Hematology (2.3k citations), Genetics (1.6k citations), Pathology and Forensic Medicine (2.4k citations), Immunology (2.7k citations) and Oncology (2.2k citations). Peter Vandenberghe has collaborated with scholars based in Belgium, United States and Netherlands. Frequent co-authors include Jan Ceuppens, Gregor Verhoef, Jan Cools, Iwona Włodarska, Sigrid Stroobants, Karoline Spaepen, José Thomas, Mark de Boer, Patrick Dupont and Peter Marynen. Their work appears in journals such as Blood, Haematologica, Leukemia, British Journal of Haematology and Genes Chromosomes and Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.